How Will the Market React to Adagio Therapeutics Inc (ADGI) Stock Getting a Bearish Rating

Wednesday, July 27, 2022 01:45 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to Adagio Therapeutics Inc (ADGI) Stock Getting a Bearish Rating

The market has been down on Adagio Therapeutics Inc (ADGI) stock recently. ADGI gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Adagio Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ADGI!

See Full ADGI Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ADGI Stock Today?

Adagio Therapeutics Inc (ADGI) stock is lower by -0.26% while the S&P 500 is up 1.36% as of 1:40 PM on Wednesday, Jul 27. ADGI is down -$0.01 from the previous closing price of $3.91 on volume of 156,041 shares. Over the past year the S&P 500 has fallen -10.41% while ADGI is down -81.32%. ADGI lost -$3.08 per share in the over the last 12 months.

More About Adagio Therapeutics Inc

Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. Click Here to get the full Stock Report for Adagio Therapeutics Inc stock.